Affiliation
University of Leeds, St James' University Hospital, Leeds, UK. fjcollinson@doctors.org.ukIssue Date
2009-02
Metadata
Show full item recordAbstract
PURPOSE OF REVIEW: Despite advances in management over recent years, epithelial ovarian cancer remains the most lethal gynaecological malignancy. Methods of early detection, as well as improved therapeutic options, are urgently needed. RECENT FINDINGS: Currently, a number of targeted therapies, including vascular endothelial growth factor inhibitors, poly-ADP-ribose polymerase inhibitors and folate receptor inhibitors look promising in this arena and this article will review a number of these drugs and the evidence pertaining to their use. SUMMARY: Much further research is required to define if, when and how best to integrate these novel therapies, and also to define associated biomarkers that predict toxicity and select patients most likely to derive benefit. Individualized therapy is not an impossible dream, but there is still a long way to go.Citation
New therapeutic agents in ovarian cancer. 2009, 21 (1):44-53 Curr. Opin. Obstet. Gynecol.Journal
Current Opinion in Obstetrics & GynecologyDOI
10.1097/GCO.0b013e32831ffe71PubMed ID
19125003Type
ArticleBook
Language
enISSN
1473-656Xae974a485f413a2113503eed53cd6c53
10.1097/GCO.0b013e32831ffe71
Scopus Count
Related articles
- Targeted agents in ovarian cancer.
- Authors: Kristedja TS, Morgan RJ, Cristea M
- Issue date: 2010 Sep
- Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Authors: Dhillon S
- Issue date: 2013 Aug
- Angiogenesis inhibitors for the treatment of ovarian cancer.
- Authors: Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J
- Issue date: 2011 Sep 7
- New drugs for ovarian cancer.
- Authors: Kaye SB
- Issue date: 2008 Feb
- Bevacizumab in the treatment of ovarian cancer.
- Authors: Han ES, Monk BJ
- Issue date: 2007 Oct